28 Capsules Regorafenib 40mg RET Hepatocellular Carcinoma Drugs

Regorafenib (Byvango Stivarga)
Drug Name
Generic Name: Regorafenib Tablets

Trade name: Stivarga Bavango

English name: Regorafenib Tablets

Hanyu Pinyin: Ruigefeini Pian

Indications
Indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have received prior fluorouracil, oxaliplatin and irinotecan-based chemotherapy, and who have received prior or unsuitable anti-VEGF therapy or anti-EGFR therapy (RAS wild-type).

Patients with locally advanced, inoperable or metastatic gastrointestinal mesenchymal stromal tumor (GIST) who have received prior treatment with imatinib mesylate and sunitinib malate.

[Dosage]
Regorafenib should be prescribed by a physician experienced in the administration of anticancer therapy.

Recommended Dosage

The recommended dose is 160 mg (4 tablets, each tablet contains 40 mg of regorafenib), taken orally once daily for the first 21 days of each course of treatment, for a period of 28 days.

Directions

Regorafenib tablets should be swallowed whole with water at the same time each day after a low-fat breakfast (30% fat). Patients should not take two doses on the same day to make up for a missed dose (from the previous day). If vomiting occurs after taking regorafenib, patients should not take another dose on the same day.

Duration of treatment

Treatment should be continued until the patient fails to benefit clinically or develops an intolerable toxic reaction.

Dose Adjustments and Special Instructions for Use

Based on individual safety and tolerability considerations, it may be necessary to interrupt administration or reduce the dose. Dose adjustments of 40 mg (one tablet) per dose should be used. The recommended minimum daily dose is 80 mg. the maximum daily dose is 160 mg.

[Adverse Reactions]
The most common adverse drug reactions (≥30%) in patients treated with regorafenib were weakness/fatigue, skin reactions of the hands and feet, diarrhea, decreased appetite and eating, hypertension, vocal difficulties, and infections.

The most serious adverse drug reactions in patients treated with regorafenib were severe liver injury, bleeding, and gastrointestinal perforation.

[Storage].
Keep sealed below 25°C. Keep the medicine out of the reach of children. There is desiccant in the cap to prevent accidental ingestion. Please keep the cap tightly closed to avoid heat and moisture.